Topical KINOSTAT ameliorates the clinical development and progression of cataracts in dogs with diabetes mellitus

Peter F Kador, Terah R. Webb, Dineli Bras, Kerry Ketring, Milton Wyman

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective To determine whether topical administration of the aldose reductase inhibitor Kinostat™ can ameliorate the onset or progression of cataracts in dogs with naturally occurring diabetes mellitus (DM).Materials and Methods A randomized, prospective, double-masked placebo control pilot study was conducted with 40 dogs newly diagnosed with DM with no or minimal lens changes. Twenty-eight dogs received Kinostat™ and 12 dogs received placebo.Procedures Owners administered the agent into both eyes three times daily for 1 year and compliance was monitored with log sheets. Complete ophthalmic examinations were performed on dilated eyes at the time of enrollment and 1, 2, 3, 6, and 12 months into treatment. Cataract severity was assessed on a scale of 0-3. At 12 months, full bloodwork, including HbA1C and blood Kinostat levels were performed.Results After 12 months of treatment, the cataract score in the placebo group significantly increased with seven dogs (14 eyes) developing mature cataracts, two dogs (4 eyes) developing cortical opacities, and one dog (2 eyes) developing equatorial vacuoles with mild punctate cortical opacities. In contrast, the cataract score in the Kinostat treated dogs was significantly less with seven developing anterior equatorial vacuoles, two developing incipient anterior cortical cataracts, and four developing mature cataracts. In fact, the cataract scores of the Kinostat group at 12 months did not significantly increase from the score at the time of enrollment. The HbA1C values between the two groups after 12 months of treatment were similar, and no blood levels of Kinostat were found in any enrolled dog.Conclusion The onset and/or progression of cataracts in dogs with DM can be significantly delayed by topical administration of Kinostat™.

Original languageEnglish (US)
Pages (from-to)363-368
Number of pages6
JournalVeterinary Ophthalmology
Volume13
Issue number6
DOIs
StatePublished - Nov 1 2010

Fingerprint

cataract
diabetes mellitus
Cataract
Diabetes Mellitus
Dogs
dogs
eyes
placebos
Topical Administration
opacity
Placebos
Vacuoles
vacuoles
aldehyde reductase
Aldehyde Reductase
blood
Lens
compliance
Lenses
Compliance

Keywords

  • Aldose reductase inhibitor
  • Cataracts
  • Diabetes mellitus
  • Dogs
  • Treatment

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Topical KINOSTAT ameliorates the clinical development and progression of cataracts in dogs with diabetes mellitus. / Kador, Peter F; Webb, Terah R.; Bras, Dineli; Ketring, Kerry; Wyman, Milton.

In: Veterinary Ophthalmology, Vol. 13, No. 6, 01.11.2010, p. 363-368.

Research output: Contribution to journalArticle

Kador, Peter F ; Webb, Terah R. ; Bras, Dineli ; Ketring, Kerry ; Wyman, Milton. / Topical KINOSTAT ameliorates the clinical development and progression of cataracts in dogs with diabetes mellitus. In: Veterinary Ophthalmology. 2010 ; Vol. 13, No. 6. pp. 363-368.
@article{70e6ac5704bb4cc0bbb8ab0b33bee600,
title = "Topical KINOSTAT™ ameliorates the clinical development and progression of cataracts in dogs with diabetes mellitus",
abstract = "Objective To determine whether topical administration of the aldose reductase inhibitor Kinostat™ can ameliorate the onset or progression of cataracts in dogs with naturally occurring diabetes mellitus (DM).Materials and Methods A randomized, prospective, double-masked placebo control pilot study was conducted with 40 dogs newly diagnosed with DM with no or minimal lens changes. Twenty-eight dogs received Kinostat™ and 12 dogs received placebo.Procedures Owners administered the agent into both eyes three times daily for 1 year and compliance was monitored with log sheets. Complete ophthalmic examinations were performed on dilated eyes at the time of enrollment and 1, 2, 3, 6, and 12 months into treatment. Cataract severity was assessed on a scale of 0-3. At 12 months, full bloodwork, including HbA1C and blood Kinostat™ levels were performed.Results After 12 months of treatment, the cataract score in the placebo group significantly increased with seven dogs (14 eyes) developing mature cataracts, two dogs (4 eyes) developing cortical opacities, and one dog (2 eyes) developing equatorial vacuoles with mild punctate cortical opacities. In contrast, the cataract score in the Kinostat™ treated dogs was significantly less with seven developing anterior equatorial vacuoles, two developing incipient anterior cortical cataracts, and four developing mature cataracts. In fact, the cataract scores of the Kinostat™ group at 12 months did not significantly increase from the score at the time of enrollment. The HbA1C values between the two groups after 12 months of treatment were similar, and no blood levels of Kinostat™ were found in any enrolled dog.Conclusion The onset and/or progression of cataracts in dogs with DM can be significantly delayed by topical administration of Kinostat™.",
keywords = "Aldose reductase inhibitor, Cataracts, Diabetes mellitus, Dogs, Treatment",
author = "Kador, {Peter F} and Webb, {Terah R.} and Dineli Bras and Kerry Ketring and Milton Wyman",
year = "2010",
month = "11",
day = "1",
doi = "10.1111/j.1463-5224.2010.00826.x",
language = "English (US)",
volume = "13",
pages = "363--368",
journal = "Veterinary Ophthalmology",
issn = "1463-5216",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Topical KINOSTAT™ ameliorates the clinical development and progression of cataracts in dogs with diabetes mellitus

AU - Kador, Peter F

AU - Webb, Terah R.

AU - Bras, Dineli

AU - Ketring, Kerry

AU - Wyman, Milton

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Objective To determine whether topical administration of the aldose reductase inhibitor Kinostat™ can ameliorate the onset or progression of cataracts in dogs with naturally occurring diabetes mellitus (DM).Materials and Methods A randomized, prospective, double-masked placebo control pilot study was conducted with 40 dogs newly diagnosed with DM with no or minimal lens changes. Twenty-eight dogs received Kinostat™ and 12 dogs received placebo.Procedures Owners administered the agent into both eyes three times daily for 1 year and compliance was monitored with log sheets. Complete ophthalmic examinations were performed on dilated eyes at the time of enrollment and 1, 2, 3, 6, and 12 months into treatment. Cataract severity was assessed on a scale of 0-3. At 12 months, full bloodwork, including HbA1C and blood Kinostat™ levels were performed.Results After 12 months of treatment, the cataract score in the placebo group significantly increased with seven dogs (14 eyes) developing mature cataracts, two dogs (4 eyes) developing cortical opacities, and one dog (2 eyes) developing equatorial vacuoles with mild punctate cortical opacities. In contrast, the cataract score in the Kinostat™ treated dogs was significantly less with seven developing anterior equatorial vacuoles, two developing incipient anterior cortical cataracts, and four developing mature cataracts. In fact, the cataract scores of the Kinostat™ group at 12 months did not significantly increase from the score at the time of enrollment. The HbA1C values between the two groups after 12 months of treatment were similar, and no blood levels of Kinostat™ were found in any enrolled dog.Conclusion The onset and/or progression of cataracts in dogs with DM can be significantly delayed by topical administration of Kinostat™.

AB - Objective To determine whether topical administration of the aldose reductase inhibitor Kinostat™ can ameliorate the onset or progression of cataracts in dogs with naturally occurring diabetes mellitus (DM).Materials and Methods A randomized, prospective, double-masked placebo control pilot study was conducted with 40 dogs newly diagnosed with DM with no or minimal lens changes. Twenty-eight dogs received Kinostat™ and 12 dogs received placebo.Procedures Owners administered the agent into both eyes three times daily for 1 year and compliance was monitored with log sheets. Complete ophthalmic examinations were performed on dilated eyes at the time of enrollment and 1, 2, 3, 6, and 12 months into treatment. Cataract severity was assessed on a scale of 0-3. At 12 months, full bloodwork, including HbA1C and blood Kinostat™ levels were performed.Results After 12 months of treatment, the cataract score in the placebo group significantly increased with seven dogs (14 eyes) developing mature cataracts, two dogs (4 eyes) developing cortical opacities, and one dog (2 eyes) developing equatorial vacuoles with mild punctate cortical opacities. In contrast, the cataract score in the Kinostat™ treated dogs was significantly less with seven developing anterior equatorial vacuoles, two developing incipient anterior cortical cataracts, and four developing mature cataracts. In fact, the cataract scores of the Kinostat™ group at 12 months did not significantly increase from the score at the time of enrollment. The HbA1C values between the two groups after 12 months of treatment were similar, and no blood levels of Kinostat™ were found in any enrolled dog.Conclusion The onset and/or progression of cataracts in dogs with DM can be significantly delayed by topical administration of Kinostat™.

KW - Aldose reductase inhibitor

KW - Cataracts

KW - Diabetes mellitus

KW - Dogs

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=78349266468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349266468&partnerID=8YFLogxK

U2 - 10.1111/j.1463-5224.2010.00826.x

DO - 10.1111/j.1463-5224.2010.00826.x

M3 - Article

C2 - 21182720

AN - SCOPUS:78349266468

VL - 13

SP - 363

EP - 368

JO - Veterinary Ophthalmology

JF - Veterinary Ophthalmology

SN - 1463-5216

IS - 6

ER -